vTv Therapeutics Inc. Class A Common Stock (VTVT)
Stock · NASDAQ · Health Care
$26.54as of 10/16/2026
Price chart
Active signals
VTVT Signal Track Record
How signals performed across all stocks →What VTVT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 24 | -8.0% | 38% | September 29, 2026 |
| Bollinger Band BreakdownActive now | 22 | +3.3% | 59% | September 15, 2026 |
| Bollinger Band Breakout | 20 | -3.2% | 40% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -0.9% | 43% | August 25, 2026 |
| Any 20-session window (baseline) | -1.9% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VTVT
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 26
- Website
- vtvtherapeutics.com/
Fundamentals
- 1-day range
- $25.95$27.49
- Market cap
- $136.33M
- P/E (trailing)
- 55.59
- P/E (forward)
- -6.06
- EPS (trailing)
- $-1.06
- Dividend yield
- —
- Beta
- 0.23
- Avg. volume
- 63.5K
How vTv Therapeutics Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 20, 2025 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
vTv Therapeutics Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- VTVTvTv Therapeutics Inc. Class A Common Stock$26.54▼ 3.81%Market cap $136.33MP/E 55.59$19.5$44
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$0.906▲ 0.00%Market cap $137.89MP/E —$0.8501$3.82
- HURATuHURA Biosciences Inc. Common Stock$1.76▼ 3.83%Market cap $134.69MP/E —$0.41$3.43
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
- EQEquillium Inc. Common Stock$1.19▼ 9.85%Market cap $134.04MP/E —$0.76$3.54
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VTVT vTv Therapeutics Inc. Class A Common Stock | $136.33M | 55.59 | $26.54 | ▼ 3.81% | $19.5$44 |
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $137.89M | — | $0.906 | ▲ 0.00% | $0.8501$3.82 |
| HURA TuHURA Biosciences Inc. Common Stock | $134.69M | — | $1.76 | ▼ 3.83% | $0.41$3.43 |
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
| EQ Equillium Inc. Common Stock | $134.04M | — | $1.19 | ▼ 9.85% | $0.76$3.54 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BTIG Reiterates Buy on vTv Therapeutics, Maintains $57 Price Targetbenzinga · 10/14/2026
- vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026Yahoo · 10/10/2026
- vTv Therapeutics stock jumps on FDA orphan drug statusYahoo · 10/8/2026
- vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseYahoo · 10/7/2026
- vTv Therapeutics Receives FDA's Orphan Drug Designation For HPPD To Treat Sickle Cell DiseaseBenzinga · 10/7/2026
- vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026Yahoo · 10/6/2026
- vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)Yahoo · 10/5/2026
- vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes TrialBenzinga · 10/5/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.47M
- Total value held
- $58.29M
- Institutional holders
- 33
- Unknown298.5K
- Unknown260.4K
- Unknown206.3K
- Unknown163.0K
- Unknown148.3K
- Unknown139.6K
- Unknown108.9K
- Unknown32.9K
- Unknown18.1K
- Unknown16.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment
vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment. vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.